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Crystal agglomeration is a major element in calcium oxalate
urinary stone formation
DIK J. KOK, SOCRATES E. PAPAPOULOS, and OLAV L.M. BIJVOET
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Crystal agglomeration is a major element in calcium oxalate urinary
stone formation. The effects of urines from 36 healthy subjects and 86
calcium oxalate renal stone formers on calcium oxalate monohydrate
crystallization kinetics were studied using a seeded crystal growth
method in which the solubility, the growth and the agglomeration of the
crystals are measured as three separate and system-independent param-
eters. The urines of healthy subjects were found to increase the
solubility and to strongly inhibit the growth and the agglomeration of
calcium oxalate monohydrate crystals. The urines of stone formers had
a similar effect on the solubility, but a significantly lower ability to
inhibit the crystal growth and the crystal agglomeration. Of these two
kinetic processes the inhibition of crystal agglomeration was more
clearly affected, with 55% of the stone formers having abnormally low
values, while the changes in crystal growth inhibition occurred within
the normal range. The defect in crystal agglomeration inhibition was
related to stone frequency, and urines from patients with very high
stone frequency rates had also the most severely impaired ability to
inhibit the agglomeration of the calcium oxalate monohydrate crystals.
The inhibitory effect of urines on crystal agglomeration was found to be
related to its citrate content (r 0.68, P < 0.001). All patients with
hypocitraturia, except two, had also abnormally low values for crystal
agglomeration inhibition. In a group of 15 hypocitraturic stone formers,
alkali treatment for a mean period of 18 months resulted in a parallel
increase in urinary citrate excretion and in the ability of urines to inhibit
crystal agglomeration (r = 0.77, P < 0.001). These results show that
defective inhibition of the kinetic process of crystal agglomeration
constitutes a major physicochemical mechanism of calcium oxalate
renal stone formation, which appears to be modulated by urinary citrate
concentrations.
Renal stone formation is a biological process that involves a
physicochemical element, crystallization. The two major as-
pects of crystallization are a thermodynamic one which in-
cludes supersaturation leading to nucleation, and a kinetic one
which comprises the rates of nucleation, crystal growth and
crystal agglomeration. The composition of the urine affects
each of these processes differently. The combination of the
interactions determines whether crystallization will be limited
to the production of freely excretable particles in the urine or
will end in stone formation. The mechanisms underlying these
interactions and their relative contribution to stone formation
are not known. Factors, for example, which lead to high urinary
supersaturation with calcium oxalate, such as increased con-
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centrations of calcium and/or oxalate, are generally considered
as important risk factors, since crystallization must obviously
start from supersaturation. Though this may be true for a
number of stone formers, there remains a substantial proportion
of patients with calcium oxalate stones and normal urinary
calcium and oxalate excretion rates. Equally striking is that
supersaturation and crystalluria may periodically occur in
healthy persons without leading to stone formation [1, 2]. The
kinetic processes of crystal growth and crystal agglomeration
may actually be the decisive elements in stone formation.
Several urinary compounds have been shown to strongly
affect the processes of crystal growth and agglomeration under
controlled experimental conditions [3]. Direct extrapolation of
these in vitro data to the more complex urinary conditions is of
course dangerous, but in a preliminary study of a small selected
group of renal stone formers with very high stone production
rate, we found clear evidence for a disturbance of the process of
crystal agglomeration [4]. These observations suggested that
the kinetic processes involved in crystallization of calcium
oxalate could be of primary importance in renal stone forma-
tion.
In the present study we measured separately the effects of
urines from healthy subjects and from a large group of calcium
oxalate stone formers with variable stone formation rates on the
solubility, growth, and agglomeration of calcium oxalate mono-
hydrate crystals. We also examined the relationship between
the concentration of various urinary constituents and the mea-
sured effects of the same urines on these parameters of crys-
tallization.
Methods
Physicochemical parameters
The effects of urines on the calcium oxalate monohydrate
crystallization kinetics were determined with a seeded crystal
growth system which has been described in detail before [3,
5—81. This system is based on a complete description of the
calcium oxalate monohydrate growth kinetics [5—8] and the
effects of the ionic strength, the calcium to oxalate ratio, the
supersaturation (varying), the seed concentration, the crystal
growth, and the crystal agglomeration on the measured growth
kinetics are accounted for. In this system the solubility, the
growth and the agglomeration of calcium oxalate monohydrate
crystals are thus measured as three separate, system-indepen-
dent parameters and are expressed: solubility, ,,/Lc, (mM),
growth inhibition, %G.I., and agglomeration inhibition, [tm] in
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(minutes). The essentials of the method, in brief, are as follows.
Supersaturated solutions were prepared with initial total con-
centrations of calcium and oxalate of 0.372 m, and were
buffered at pH 6.00 with 7.5 m sodium dimethylarsinate. A
tracer amount of 45Ca was added and the solutions were
brought to an ionic strength of 0.15 M with sodium chloride.
Urines were tested in a 1:5 dilution with these solutions and
each measurement was always accompanied by a control
experiment without addition of urine but under otherwise
identical conditions. The experiments, performed at 37°C,
started by seeding with calcium oxalate monohydrate crystals
in a known seed concentration. The crystals used were aged for
over one year and dried. Before each experiment, the seed
material was pregrown under slightly supersaturated conditions
for 3.5 hours, to ensure reproducibility in crystal surface
properties between each experiment. By keeping seed material
in a homogenous suspension, an exactly known amount could
be reproducibly sampled and added to each experiment. Un-
wanted systemic influences due to uncontrolled variations in
type and amount of seed crystals were thus ruled out. During
the experiments, the crystals were kept in suspension by
shaking. At various times, after incubation, the crystals were
collected on a millipore filter (0.45 p) and fractional uptake, of
45Ca tracer into the crystals was measured. Errors in the
measured uptake due to exchange processes and aspecific
tracer absorption to the filter and crystal mass, was less than 1%
in our system [5—8]. As described in detail before [3, 5—8] the
solubility of calcium oxalate monohydrate was obtained di-
rectly from experiments in which growth time was kept con-
stant but starting calcium-oxalate product varied. It was mea-
sured as the lowest concentration product after which uptake of
calcium due to growth of the seed crystals starts to occur, thus,
it was the equilibrium concentration product. There are two
major advantages of our method for directly measuring effects
on solubility by unknown additives. The first is that only
calcium and oxalate concentrations need to be determined;
further knowledge of the composition of the additive is not
needed, which is in contrast to computer derived estimations of
the solubility. The second is that the method is less time
consuming compared to equilibration experiments. The growth
kinetics are obtained from an experiment in which starting
supersaturation is kept constant but growth time is varied.
Since the solubility has exactly been determined, and systemic
influences have been excluded or accounted for, the true
contributions of the crystal growth and the crystal agglomera-
tion to the measured growth kinetics can now be calculated
using the complete description of calcium oxalate monohydrate
growth kinetics [3, 5—81. Agglomeration reduces the rate at
which mineral components are taken up by a crystal mass,
probably due to a decrease in accessible crystal surface. It can,
therefore, be measured from this rate-decreasing effect and is
expressed in units of time, [tm] in minutes. Crystal growth is
measured as the crystal growth constant, which depends only
on the crystal surface characteristics. Inhibition of crystal
growth, caused by binding of compounds to the overall crystal
surface or, more specifically, to the growth sites, is measured as
a decrease in crystal growth constant as compared to the
control experiment, and is expressed as a percentage of the
latter, %G.I.
Urines were collected with thymol crystals as preservative.
These crystals were removed by filtration through normal filter
paper, pH was measured, and the urine was buffered at pH 6.00
and used immediately or stored under toluene until assay within
24 hours. The coefficient of variation for all three physicochem-
ical parameters measured in different assays on the same day or
on different days was less than 5%.
Biochemical parameters
Calcium and magnesium were measured by atomic absorp-
tion spectrophotometry, sodium and potassium by flamepho-
tometry, chloride by a coulombmetric method, phosphate by
the molybdate complex technique and creatinine by an auto-
mated technique in an auto-analyzer. Enzymatic methods were
used for uric acid (urikase), oxalate (oxoxidase) and citrate
(using citrate lyase in an adaption of the enzymatic method of
Moellering et a! [9]).
Patients
Urines from 86 calcium oxalate stone formers were studied.
These were 75 men and 11 women aged between 17 and 76 years
(mean age 49.6 years). At the time of the study all patients had
normal renal function and sterile urine cultures. Renal stones,
either spontaneously passed or surgically removed, were found
by infrared spectrophotometry to consist predominantly of
calcium oxalate (more than 50%). The stone frequency was 3.3
stones per patient per year, or one stone per patient per year
after excluding seven patients who had very high recurrence
rates. All patients were included in the analysis of the results.
Before installment of any treatment and while the patients were
on a free diet, two consecutive, 24-hour urine collections were
obtained from each of them for the measurement of creatinine,
calcium, oxalate, citrate, magnesium and uric acid. The bio-
chemical abnormalities found were: hypercalciuria (urinary
calcium excretion > 7.5 mmolI24 hrs) in 44 (51%) patients,
hyperoxaluria (urinary oxalate excretion > 0.50 mmol/24 hrs) in
16 (19%) patients, hypocitraturia (citrate excretion < 2.0 mmol/
24 hrs) in 39 (45%) patients and hyperuricosuria (uric acid
excretion > 6.0 tnmolI24 hrs) in 15 (17%) patients. In 38 (44%)
patients more than one abnormality was present while in 10
(12%) the excretion rates of all measured substances were
found to be within the respective normal ranges.
One further 24-hour urine collection was obtained from all
patients for the measurement of the three physicochemical
parameters and of creatinine, calcium, oxalate, citrate, magne-
sium, phosphate, uric acid, sodium, potassium, chloride and
pH. In 15 patients with hypocitraturia these measurements
were repeated after treatment with alkali for a mean period of 18
months (range 2 to 40 months). The administration of alkali
consisted of sodium- or potassium bicarbonate (13 patients), or
sodium-potassium citrate (6 patients, four of whom had re-
ceived bicarbonate before).
For comparison, urinary composition and crystallization pa-
rameters were studied in 36 healthy subjects with no history of
urolithiasis. These were 27 men and 9 women aged between 22
and 72 years (mean age 41.5 years). None was taking any
medication. All had normal renal function and no evidence of
urinary tract infection. Eight of them were studied while on a
high fluid intake, since a number of stone formers had already
been given drinking advice at the time of assessment of the
physicochemical parameters.
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Para- Heaithy (N = 36) Patients (N = 86)
meters Mean SEM Range Mean SEM Range
JLc msi 0.237 0.010 0.172—0.376 0.236 0.005 0.168—0.395
% G.I. 84.8
[tm] mm 275
15
23
57—97
145—584
78
172b
1
13
55—97
35—715
Statistics
Differences between groups were tested for their significance
using the Student's t-test, paired or unpaired, or the Mann-
Whitney test (nonparametric). Correlations between measured
parameters were obtained using simple and multiple linear
regression analysis with the NCCS software, if necessary after
logarithmic transformation of not normally distributed values.
Results are expressed as means SEM.
The number of women in both the patient and control groups
was too small to allow separate analysis of possible sex differ-
ences in the physicochemical or biochemical parameters tested.
Results
The effects of urines of the healthy persons and of the stone
formers on the three physicochemical parameters are shown in
Table 1.
Urines from the healthy subjects clearly increased the solu-
bility of calcium oxalate monohydrate from a control value of
0.167 m to a maximum of 0.376 mM (mean 0.237 0.010 mM).
Similarly, urines from stone formers increased the solubility to
a maximum of 0.395 ifiM (mean 0.236 0.005 mM). There was
no difference between the two groups.
Crystal growth was inhibited strongly by the urines of both
groups. The degree of inhibition, however, was significantly
lower in the patients, though the ranges overlapped completely.
Urines from healthy subjects strongly inhibited the agglom-
eration of calcium oxalate monohydrate crystals. In contrast, in
55% of the stone former group [tm] values were found below the
lower limit of normal and in 14% of them the urine was entirely
unable to inhibit crystal agglomeration (no significant difference
from the control experiments). The ability, thus, of the urines of
stone formers to inhibit the growth and the agglomeration of
calcium oxalate monohydrate crystals was impaired relative to
urines from healthy persons.
Between these two physicochemical parameters the inhibi-
tion of crystal agglomeration distinguished the two groups best.
To obtain insight in the possible relation between impaired
urinary ability to inhibit crystal agglomeration and propensity to
stone formation, we examined the relation between [tm] and
stone frequency. As shown in Figure 1, with increasing stone
frequency there was a progressive decrease in [tm}, the lowest
values occurring in the patients with the very high stone
frequency.
We further studied the relation between the agglomeration
inhibitory ability and the chemical composition of the urines.
The results are shown in Table 2. Of all measured substances
Fig. 1. Calcium oxalate ,nonohydrate crystal agglomeration inhibition
(1 tmj) in urines of healthy subjects (N = 36) and of stone formers (N =
84), mean SEM. Stone frequency denotes stones per patient during the
5 years preceding the study. The [tm] values of 0—1 (N = 38), 2—5 (N =
28) and> 5 (N = 18) are significantly lower than normal (P values of
0.014, <0.0001 and <0.0001, respectively). The [tm] values for 2—5 and
> 5 are significantly decreased relative to those of 0—1, (P values 0.0089
and 0.0005, respectively). Significance was tested with the Mann-
Whitney test.
Stone
—
Hea
Mean
ithy
SEM
formers
Mean SEM P
Volume ml 1868 132 1952 87 NS
Creatinine mmol/24 hr 14.82 0.72 13.80 0.63 NS
Calcium mmol/24 hr 4.86 0.33 6.30 0.30 0.004
Oxalate mmo!/24 hr 0.31 0.01 0.37 0.01 0.001
Citrate mmol/24 hr 3.81 0.25 2.46 0.14 <0.0001
Phosphate mmol/24 hr 30.52 1.89 30.54 1.20 NS
Magnesium mmol/24 hr 5.03 0.28 4.52 0.18 NS
Uric acid mmol/24 hr 4.86 0.22 4.67 0.18 NS
Sodium mmo!/24 hr 155 9 170 8 NS
Potassium mmol/24 hr 70.5 4.2 75.6 3.5 NS
Chloride mmo!/24 hr 158 9 168 8 NS
pH 6.25 0.06 6.24 0.06 NS
only the excretion rates of calcium, oxalate and citrate were
found to differ significantly between the two groups of subjects.
By multivanant analysis, citrate was found to be the major
contributor to agglomeration inhibition. Actually all patients
with hypocitraturia, except two, also had abnormally low
values for crystal agglomeration inhibition (Fig. 2). The corre-
lation between the citrate content of urine and its inhibitory
effect on agglomeration was highly significant (r= 0.68, P <
0.001, N 86, after logarithmic transformation, Fig. 2). No
correlation between age and either [tm] or urinary citrate was
found.
To examine the effect of citrate on the crystallization of
calcium oxalate monohydrate further, we studied 15 hypocitra-
turic patients before and after treatment with alkali. This
treatment increased urinary citrate excretion in all patients and
the mean value rose from 1.28 0.42 mmolI24 hrs to 3.05
Table I. Effects of urines from healthy subjects and stone formers
on calcium oxalate monohydrate crystallization kinetics
Abbreviations are ILc, solubility; % G.I., growth inhibition; [tm},
agglomeration inhibition.
ap = 0,001b P <0.0001
E
E
300
200
100
0
Stone frequency
Table 2. Urinary composition in healthy subjects (N = 36) and in
stone formers (N 86)
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Fig. 2. A. The relation between calcium oxalate monohydrate crystal
agglomeration inhibition (Etmi) and citrate excretion rates in urines of 86
stone formers. Lines represent the lower limits of the respective normal
ranges. B. The relation between the natural logarithms of crystal
agglomeration inhibition ([tm]) and urinary citrate concentrations in the
stone formers.
1.09 mmolI24 hrs (P < 0.001, paired (-test). The [tm], which was
abnormally low in all, increased with treatment from a mean
value of 83 8 minutes to a mean value of 178 17 minutes (P
< 0.0001, paired (-test) and became normal in 10 of the 15
patients (Fig. 3). In these treated patients, citrate excretion was
significantly correlated with [tm] as well (r = 0.77, P < 0.001, N
= 30). Alkali treatment had no effect on solubility, which was
0.212 0.008 m before treatment and 0.2 16 0.012 m after
treatment. A variable, but significant increase in crystal growth
inhibition was found, from a mean of 73 1% to 82 2% (P <
0.001, paired (-test). This increase, however, was not observed
in all patients and occurred well within the normal range (Fig.
4).
Discussion
Urines from healthy subjects were found to have a favorable
action on both the thermodynamic and the kinetic components
of calcium oxalate crystallization. They increased the solubiity
and they inhibited both the growth and the agglomeration of
calcium oxalate monohydrate crystals. In contrast, in the urines
from renal stone formers mainly the control of the kinetic
processes was impaired.
Considering the mechanism of renal stone formation, it is
evident that supersaturation of urine with calcium oxalate is
essential. The lack of difference in the solubility between urines
from healthy subjects and stone formers may, therefore, appear
surprising. Supersaturation, however, is not only determined
by the solubility product, but also by the concentrations of
calcium and oxalate in the urine which were indeed found to be
2 significantly higher in the stone formers. The net result would,
therefore, be a higher mean supersaturation with calcium ox-
alate in the urines of stone formers, as has been previously
shown by others [10]. This higher supersaturation will increase
the risk of calcium oxalate crystal formation but not necessarily
the risk of renal stone formation. It is well known, for example,
that small particles can be formed and excreted in the urine
without causing any problem and healthy subjects can exhibit
significant degrees of crystalluria without forming renal stones
[1, 2].
The crucial element in stone formation is the size of the
particles formed, and this is mainly governed by the kinetic
processes of crystal growth and crystal agglomeration. Effects
on each of these two processes were significantly impaired in
the renal stone formers examined but to a different degree.
Urines from the stone former group inhibited calcium oxalate
crystal growth significantly less than urines from healthy sub-
jects, but the remaining inhibitory activity was still consider-
able. These variations occurred within the normal range and it
was impossible to differentiate between the two groups on an
individual basis. It seems, therefore, highly unlikely that the
formation of renal stones is caused by this small decrease in
crystal growth inhibition. This result is also in agreement with
theoretical considerations denouncing crystal growth as the
determinant process in the formation of large particles [11]. A
single crystal can never reach a size large enough to remain in
the narrow parts of the urinary tract by the slow process of
A
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Fig. 3. Calcium oxalate monohydrate crystal agglomeration (1 tmj) and
citrate excretion rates in urines of 15 hypocitraturic patients before (0)
and after (•) alkali treatment.
S S
•.SS 55 •5•
.
•.''!'
•:s'• S.
• SSS S
3
—2 —1 0 1
C02 80
.0
-CC
0
c 70
crystal growth alone, even if this process proceeds at an
uninhibited rate [11, 121. In contrast, large particles can be
formed within a short period by the fast process of crystal
agglomeration, and the average renal stone clearly has an
agglomerate structure [13—161. These observations suggest that
crystal agglomeration plays the major role in the formation of
large particles and that adequate control of this process is of
primary importance for the protection against calcium oxalate
stone formation. Our results in healthy subjects show that
normal urines can strongly inhibit crystal agglomeration. In
more than half of the stone formers this ability is clearly
diminished and in a number of them it is even completely
absent. This is the first time that a single physicochemical
parameter is found to differentiate healthy subjects from stone
formers. The importance of this parameter was further con-
firmed by the finding that the impaired inhibitory activity of the
urines on the process of crystal agglomeration was clearly
related to the stone frequency. The lower the degree of control
of crystal agglomeration the higher the stone frequency, which
conforms our previous findings in a small selected group of
highly recurrent stone formers [4].
The question that arises is which factor(s) modulates the
process of agglomeration. Studies from several laboratories
have implicated both low and high molecular weight substances
present in the urine, as important regulators of crystal agglom-
eration. In none of these studies, however, was agglomeration
ever measured as a separate, independent parameter. Using the
system described briefly here [3, 5—8], we recently showed in
studies with pure compounds that citrate is a very potent
inhibitor of crystal agglomeration [3]. The present results show
that in urine as well citrate is a major modulator of this process.
In nearly all patients with hypocitratuna this was associated
with impaired ability of the urines to inhibit crystal agglomera-
tion and the correlation between these two was quite close.
Furthermore, alkali treatment given to hypocitraturic patients,
not only increased urinary citrate excretion but resulted also in
a parallel increase in the ability of the urines to inhibit crystal
agglomeration. This now provides a physicochemical explana-
tion for the favorable effect of alkali treatment in renal stone
formers [4, 17, 18]. This treatment increased also the crystal
growth inhibition, but this effect was small.
Impaired inhibition of crystal agglomeration constitutes,
therefore, a major risk factor for renal stone formation. The
largest abnormalities occur in those patients in whom recur-
rence rates are highest and who are also the most difficult to
treat. The process of crystal agglomeration in the urine appears
to be primarily modulated by citrate. The causes of hypocitra-
turia as well as the precise mechanism of action of citrate on the
inhibition of crystal agglomeration in the urine will have to be
defined.
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